くすりのしおり

Injection
Published: 8/2018

The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
Brand name :
ILARIS solution for s.c. injection 150mg
 Active ingredient:
Canakinumab(genetical recombination)
 Dosage form:
injection
 Print on wrapping:

Effects of this medicine

This medicine inhibits excessive interleukin-1beta responsible for inflammation or organ damage caused by inflammation and improves the symptoms.
It is usually used to cryopyrin-associated periodic syndrome (familial cold autoinflammatory syndrome, Muckle-Wells syndrome, neonatal onset multisystem inflammatory disorder), hyper IgD syndrome (mevalonate kinase deficiency), TNF receptor-associated periodic syndrome, and to treat familial mediterranean fever and systemic juvenile idiopathic arthritis which doesn't have sufficient effect of existing therapies.

Before using this medicine, be sure to tell your doctor and pharmacist

  • If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
    If you are a patient with infections or suspected of them.
    If you are a patient with active tuberculosis.
    If you are suspected of tuberculosis or have a history of it.
    If you are susceptible to infections.
    If you are scheduled for vaccination with a live virus vaccine.
  • If you are pregnant or breastfeeding.
  • If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)

Dosing schedule (How to take this medicine)

  • Your dosing schedule prescribed by your doctor is ((        to be written by a healthcare professional))
  • Cryopyrin-associated periodic syndrome (familial cold autoinflammatory syndrome, Muckle-Wells syndrome, neonatal onset multisystem inflammatory disorder): In general, inject subcutaneously once every 8 weeks. The injection interval may be shortened according to your symptoms.
    Hyper IgD syndrome (mevalonate kinase deficiency), TNF receptor-associated periodic syndrome, familial mediterranean fever and systemic juvenile idiopathic arthritis: In general, inject subcutaneously once every 4 weeks.
  • Depending on your response to the treatment, this medicine may be administered over a long period of time.

Precautions while taking this medicine

Possible adverse reactions to this medicine

The most commonly reported adverse reactions include nasopharyngitis, upper respiratory infection, stomatitis, injection site reaction, headache, weight gain, rotational vertigo, and bronchitis. If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
  • fever, cold-like symptoms, general malaise [serious infections]
  • fever, sore throat [neutropenia]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.

Storage conditions and other information

For healthcare professional use only : Day Month Year

For further information, talk to your doctor or pharmacist.

Keywords Search

 

 

 

 

Advanced Search

Browse by drug name A-Z
Browse by drug name A-Z